All Cell & Gene Therapy articles
-
InterviewComputational design drives new generation of synthetic promoters
SynGenSys applies computational design strategies to engineer synthetic promoters with predictable performance characteristics for therapeutic and manufacturing applications. Professor David James discusses how tissue-specific regulatory elements are designed from genomic data to enable precise control of gene expression in contexts ranging from NK cell immunotherapy to biologic production.
-
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.
-
NewsHaem signalling pathway identified as key driver of T cell exhaustion
University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.
-
NewsStem cells from baby teeth could treat cerebral palsy
Japanese researchers have shown in a rat study that stem cells derived from naturally shed baby teeth may improve motor and cognitive impairments in chronic-phase cerebral palsy.
-
ArticlePreclinical takeaways from the World ADC Conference London
Experts from the World ADC Conference in London highlight how patient-centric, predictive preclinical tools and innovative ADC designs are improving safety, efficacy and clinical translation.
-
NewsDrug Target Review’s women in STEM
For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.
-
NewsCentrifuge technique creates functional bioengineered lymph nodes
Using a straightforward cell stacking method, researchers have regenerated functional lymph nodes, offering a potential long-lasting therapy for secondary lymphedema and creating new opportunities for immunology and oncology drug discovery.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
NewsELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.
-
NewsVirus-mimicking LENN nanoparticles deliver mRNA to bladder cancer cells
Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.
-
NewsFunctional retinal organoids improve drug testing for eye disease
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
-
ArticleFertility beyond IVF: therapeutic advances in reproductive biotech
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
-
NewsPolysaccharide microneedles: the future of cancer immunotherapy
Polysaccharide-based microneedles are emerging as a dual-action platform for cancer immunotherapy, delivering anti-cancer drugs directly to the skin while actively modulating the immune system.
-
NewsHomer1 gene discovery could lead to new ADHD therapies
A new study published has demonstrated that reducing background brain activity can sharpen attention, identifying the Homer1 gene as key to developing new targeted treatments for ADHD and related disorders.
-
NewsEngineered extracellular vesicles control immune responses
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
-
NewsNew method preserves iPS cells for regenerative medicine
Kobe University researchers have developed a new way of freeze induced pluripotent stem cells (iPS cells) directly in their culture dishes without losing viability or pluripotency.
-
NewsUltra-stable hydrogel boosts gastrointestinal wound repair
PolyU researchers have developed a new acid-resistant hydrogel inspired by natural gastric mucus that adheres far better than current treatments.
-
NewsBrain drainage repair offers potential new prevention therapies for Alzheimer’s
UVA researchers have discovered a potential treatment approach that restores the brain’s natural drainage system, offering hope for preventing traumatic brain injury-related neurodegeneration.
-
NewsHydrogel tech enables global shipping of organoid models
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
-
ArticleRNA that lasts longer and lands exactly where it should
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.